These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38045691)

  • 1. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV.
    Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C
    Front Immunol; 2023; 14():1264160. PubMed ID: 38045691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    Cai S; Liao G; Yu T; Gao Q; Zou L; Zhang H; Xu X; Chen J; Lu A; Wu Y; Li B; Peng J
    J Med Virol; 2022 Sep; 94(9):4224-4233. PubMed ID: 35585023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
    Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
    J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
    Zhan H; Gao H; Liu Y; Zhang X; Li H; Li X; Wang L; Li C; Li B; Wang Y; Dai E; Li Y
    J Med Virol; 2023 Jan; 95(1):e28428. PubMed ID: 36571267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    Corma-Gómez A; Fernández-Fuertes M; Viñuela L; Domínguez C; Santos M; Fuentes-López A; Rojas A; Fernández-Pérez N; Martín-Carmona J; Serrano-Conde E; Real LM; Mendoza J; Macías J; Pineda JA; García F
    J Med Virol; 2023 Mar; 95(3):e28602. PubMed ID: 36880164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
    Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
    Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
    Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
    Jin J; Wang X; Li Y; Yang X; Wang H; Han X; Sun J; Ma Z; Duan J; Zhang G; Huang T; Zhang T; Wu H; Zhang X; Su B
    Chin Med J (Engl); 2023 Dec; 136(24):2938-2947. PubMed ID: 37963586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis.
    Søndergaard MH; Thavarajah JJ; Churchill Henson H; Wejse CM
    HIV Med; 2024 Jan; 25(1):16-37. PubMed ID: 37731375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
    Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
    Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
    Zeng G; He F; Zhang X; Li G; Wang X; Gan Y; Zheng C; Tang J; Xu L; Zhao J; Feng S; Yang Z
    J Med Virol; 2023 May; 95(5):e28797. PubMed ID: 37218584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
    Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
    BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
    Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.